Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537439 | 0.81 | HTR2A (0.62) | TLR8TLR7KMT2AMEN1HTR2A | |
| SCHEMBL13172817 | 0.81 | HTR2A (0.44) | TLR8TLR7HTR2ATLR9 | |
| SCHEMBL537396 | 0.80 | HTR2A (0.54) | TLR8TLR7HTR2ATLR9 | |
| SCHEMBL537249 | 0.78 | HTR2A (0.45) | TLR8TLR7KMT2AKDM4EALDH1A1 | |
| SCHEMBL20016363 | 0.72 | GAA (0.49) | TLR8TLR7POLBKMT2AKDM4E | |
| SCHEMBL18324682 | 0.70 | KMT2A (0.45) | TLR8TLR7KMT2AMEN1ALDH1A1 | |
| SCHEMBL18324684 | 0.69 | TP53 (0.53) | TP53POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL18324898 | 0.68 | SMN1; SMN2 (0.49) | POLBKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL18324765 | 0.66 | HTR2A (0.52) | TLR8TLR7POLBHTR2A | |
| SCHEMBL18324710 | 0.65 | KDM4E (0.57) | POLBKMT2AKDM4EALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2414344-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | MKI67, CCNI, CDK4 | TLR8 3823/4885TLR7 2976/4885TP53 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.